Journal article icon

Journal article

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.

Abstract:

Quinagolide (CV 205-502, Sandoz), an octahydrobenzo (g) quinoline, is a new non-ergot dopamine agonist which has specific D2 receptor activity and a long half-life, making it suitable for once-daily treatment. Recent uncontrolled reports have suggested that quinagolide may be successfully used for the clinical management of hyperprolactinemia with fewer adverse reactions than bromocriptine. This study is the first to compare quinagolide in a double-blind manner with bromocriptine, given only ...

Expand abstract
Publication status:
Published

Actions


Authors


Expand authors...
Journal:
Acta endocrinologica
Volume:
125
Issue:
4
Pages:
385-391
Publication date:
1991-10-05
ISSN:
0001-5598
URN:
uuid:01c926dd-3fba-4f07-9382-ea9997ccd3d8
Source identifiers:
138394
Local pid:
pubs:138394

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP